scholarly journals Headgear-induced temporary pressure alopecia

2019 ◽  
Vol 46 (4) ◽  
pp. 335-342
Author(s):  
Catherine Liu ◽  
Faisal Abbas ◽  
Jadbinder Seehra

The development of hair loss associated with headgear use is a rare phenomenon. Pressure alopecia is a condition characterised by localised, non-scarring hair loss attributed to a mechanical cause. Factors such as prolonged periods of peri- and postoperative immobility have been implicated, as well as immunological and genetic predisposing factors. If the mechanical trauma is very prolonged, there is a risk of permanent follicle damage due to tissue hypoxia. A 13-year-old boy wore high-pull headgear as part of his orthodontic management. Within four weeks of headgear wear, localised areas of hair loss were seen corresponding with the areas of contact with the force delivery modules of the headgear. The patient experienced bullying at school as a result of this hair loss. Hair regrowth resumed after headgear use was discontinued, therefore confirming the diagnosis of temporary pressure alopecia. Temporary pressure alopecia is a rare side effect of orthodontic headgear. Alopecia can negatively impact an individual’s psychosocial wellbeing; therefore, caution should be taken to avoid prolonged or excessive pressure in susceptible individuals and headgear patients should be regularly monitored.

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Yüksel Kıvrak ◽  
İbrahim Yağcı ◽  
Mehmet Fatih Üstündağ ◽  
Halil Özcan

Hair loss is a rare side effect of psychotropic drugs. The most related drug class with this side effect is the mood stabilizers. Studies reporting the sertraline-induced alopecia are limited in number. Sertraline is a potent antidepressant which inhibits the serotonin reuptake from the presynaptic terminals selectively. The reason for hair loss could not be elucidated completely. Psychotropic drugs are usually considered to lead to hair loss through influencing the telogen phase of hair follicle. This paper reports a 21-year-old male with diffuse hair loss induced by sertraline use and improved by quitting the drug. To the best of our knowledge, there are no other case reports on sertraline-induced alopecia within 2 weeks.


2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Florence Jaguga

Abstract Background Stuttering is a rare side effect of clozapine. It has been shown to occur in the presence of one or more factors such as abnormal electrophysiological findings and seizures, extrapyramidal symptoms, brain pathology, and a family history of stuttering. Few case reports have documented the occurrence of clozapine-induced stuttering in the absence of these risk factors. Case presentation A 29-year-old African male on clozapine for treatment-resistant schizophrenia presented with stuttering at a dosage of 400 mg/day that resolved with dose reduction. Electroencephalogram findings were normal, and there was no clinical evidence of seizures. The patient had no prior history or family history of stuttering, had a normal neurological examination, and showed no signs of extrapyramidal symptoms. Conclusion Clinicians ought to be aware of stuttering as a side effect of clozapine, even in the absence of known risk factors. Further research should investigate the pathophysiology of clozapine-induced stuttering.


Rheumatology ◽  
2021 ◽  
Author(s):  
G M Murray ◽  
S Kheng Ng ◽  
D Beasley ◽  
L Johansen ◽  
A V Ramanan

Author(s):  
Varitsara Mangkorntongsakul ◽  
Chinthuran Thilagarajan ◽  
Fatemeh Arianejad ◽  
Vicki Howard ◽  
Saxon D Smith ◽  
...  

2008 ◽  
Vol 27 (2) ◽  
pp. 229-232 ◽  
Author(s):  
V. Boussaud ◽  
N. Daudet ◽  
E.M. Billaud ◽  
A. Lillo-Le Louet ◽  
P. Chevalier ◽  
...  

2020 ◽  
Vol 34 (3) ◽  
pp. 143
Author(s):  
Tsung-Hua Lu ◽  
Chien-Lin Wu
Keyword(s):  

2021 ◽  
Vol 111 (4) ◽  
Author(s):  
James A. Wright ◽  
Jessica A. Wenz ◽  
Gabrielle Jackson Madrigal

Triamcinolone acetonide is a synthetic glucocorticoid used to treat numerous acute and chronic inflammatory conditions. The various side effects of this drug from parenteral administration are well documented in the literature. In this study, three patients present with a rare side effect of violaceous dermal pigmentation. To the best of the authors' knowledge, this finding is rarely presented in the current literature. The purpose of this study is to provide awareness of a less-documented, delayed side effect from triamcinolone acetonide administration. Although all patients presenting in this study had a known history of autoimmune disease (eg, lupus, psoriatic arthritis) further research is needed to suggest a possible association between dermal violaceous change and the use of triamcinolone.


Sign in / Sign up

Export Citation Format

Share Document